Protagonist Therapeutics, Inc. (PTGX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$145.09-0.58%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Protagonist Therapeutics is growing revenue fast, nearly 100% year over year. Royalties from ICOTYDE and rusfertide are driving revenue from $7.4M to $56.4M in one quarter. Earnings per share beat estimates by 110% last quarter. The company is making progress despite being loss-making.
The company remains unprofitable and faces uncertainty in sustaining revenue growth. Analysts expect earnings to turn negative next year. The royalty growth is not yet proven to be durable or broad-based.
The stock price is about 41% above our valuation model and 18% below the Street median. Analysts expect revenue growth of about 68% next year. Our view is cautious given the loss-making status and mixed progress on royalties.
Breaks if: EPS falls below $2.24 in next quarter
Breaks if: revenue growth falls below 68% in FY2026
royalty revenue falls below $7.4M in any future quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis is intact, supported by strong recent financial performance, but it remains sensitive to market conditions and execution risks.
The market appears to be pricing in a level of fragility due to weak execution quality, despite recent positive results. PTGX is considered expensive compared to its peers, with a notable premium.
Fundamentals are likely to remain strong in the near term, given the recent earnings beats and ongoing advancements in the clinical pipeline. However, there is a moderate risk of earnings misses due to the erratic nature of the industry.
The long-term thesis hinges on management's ability to advance its clinical pipeline and achieve regulatory milestones. Additionally, the performance of sector bellwethers and overall economic conditions will be critical in shaping future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The company reported an earnings beat, which supports its thesis. The FDA approval of MIMRYLO triggers milestone payments and establishes a potential revenue stream. This shift moves the company from a pure development model to one with commercial revenue potential.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, PTGX's trajectory will depend on its execution and market conditions. Not investment advice.